Oral iron-chelating therapy: the L1 experience (Q40607123)

22 September 2017

1 reference

title

Oral iron-chelating therapy: the L1 experience (English)

1 reference

22 September 2017

F N al-Refaie

1

1 reference

22 September 2017

A V Hoffbrand

series ordinal

2

1 reference

22 September 2017

publication date

1 December 1994

1 reference

Best Practice and Research: Clinical Haematology

22 September 2017

published in

1 reference

22 September 2017

volume

7

1 reference

22 September 2017

issue

4

1 reference

22 September 2017

page(s)

941-963

1 reference

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

A comparative evaluation of iron clearance models

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

The action of chelating agents in experimental uranium intoxication in mice: variations with structure and time of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Iron chelators in medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Site specificity of iron removal from transferrin by alpha-ketohydroxypyridine chelators.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Safety of oral iron chelator L1.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Fatal systemic lupus erythematosus in patient taking oral iron chelator L1

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

The development of iron chelating drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Studies of an oral iron chelator: 1,2-dimethyl-3-hydroxy-pyrid-4-one. I. Iron excretion in rats: development of a new rapid microwave method for iron analysis in faeces

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2805%2980132-5

7 January 2021

10.1016/S0950-3536(05)80132-5

Identifiers

DOI

1 reference

22 September 2017

1 reference